Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
2016 · Cell · 3,430 citations
https://doi.org/10.1016/j.cell.2016.02.065
B
Blanca Homet Moreno
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
169
Papers
15.5K
Citations
36
h-index
58
i10-index
Blanca Homet Moreno is an academic researcher from Merck & Co., Inc., Rahway, NJ, USA (United States). The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Bladder and Urothelial Cancer Treatments & CAR-T cell therapy research. The author has an h-index of 36, co-authored 144 publications.
ORCID: 0000-0001-6712-8330Papers by this author
worksMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
2016 · New England Journal of Medicine · 3,062 citations
https://doi.org/10.1056/nejmoa1604958
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
2017 · Cell Reports · 1,821 citations
https://doi.org/10.1016/j.celrep.2017.04.031
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
2024 · New England Journal of Medicine · 810 citations
https://doi.org/10.1056/nejmoa2312117
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
2021 · Journal for ImmunoTherapy of Cancer · 140 citations
https://doi.org/10.1136/jitc-2021-002478
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
2022 · Annals of Oncology · 102 citations
https://doi.org/10.1016/j.annonc.2022.11.012
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat